01:31 AM EDT, 07/30/2026 (MT Newswires) -- Ipsen (IPN.PA) on Thursday revised its full-year 2026 outlook with its latest earnings. The biopharmaceutical company now expects total sales growth of more than 20% at constant currency, up from its previous estimate of over 13%.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.